Platelet Type Von Willebrand Disease – Diagnostic and Therapeutic Challenges
Hämostaseologie · 2026-10 · 46 (05) · 348-357
DOI: 10.1055/a-2940-6179 ↗Kurz gefasst
Fallbericht in der Zeitschrift Hämostaseologie, online erschienen am 28.08.2026. Verfasst von Rebekka Wiedenhoefer und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Freiburg Faculty of Medicine, Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Baden-Wü…. Hauptthemen laut MEDLINE: von Willebrand Diseases. Die Arbeit nennt 35 Literaturangaben. Gefördert von: CSL Behring.
Abstract (Originalsprache)
Platelet-type von Willebrand disease (PT-VWD) is a rare thrombocytopathy caused by gain-of-function variants in GP1BA, leading to increased binding of von Willebrand factor (VWF). Because its phenotype closely resembles VWD type 2B (VWD 2B), misdiagnosis is common, and distinction requires Ristocetin-induced platelet agglutination (RIPA) mixing studies and molecular genetic analysis. Although individual case reports, case series, and earlier summaries exist, an updated and comprehensive synthesis of all published cases has been lacking. We report a 4-year-old boy presenting with easy bruising, prolonged epistaxis, reduced VWF parameters (VWF collagen-binding activity 0.07 U/mL, VWF-antigen 0.33 U/mL), absence of high-molecular-weight multimers, and enhanced RIPA. Genetic testing identified the pathogenic GP1BA variant p.Met255Val, causing PT-VWD. RIPA mixing studies confirmed the diagnosis. In the course of the disease, the patient developed recurrent mucosal bleeding and a hypersensitivity reaction to tranexamic acid. Therefore, desmopressin was used, and he showed partial clinical benefit from desmopressin without developing thrombocytopenia. To contextualize this case, we performed a literature review (PubMed, May 2025) and identified 67 documented patients with PT-VWD. Over 40% were initially misclassified as VWD 2B. p.Gly249Val and p.Met255Val were the most frequent variants. Baseline thrombocytopenia occurred in approximately one-third of cases, and pregnancy-associated thrombocytopenia was common. According to the literature, platelet transfusions were most effective (in case of major hemorrhage or surgical setting); VWF concentrates or desmopressin showed variable efficacy and occasional transient thrombocytopenia. These data demonstrate the diagnostic challenges of PT-VWD and emphasize the importance of clinical case collection to improve therapeutical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Freiburg Faculty of Medicine, Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Baden-Württemberg, Germany, Freiburg.
- University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine, Germany, Bonn.
ORCID-Profile: Rebekka Wiedenhoefer, Doris Boeckelmann, Hannah Glonnegger
Förderung
- CSL Behring
Zitieren
APA
Wiedenhoefer, R., Boeckelmann, D., Glonnegger, H., Oldenburg, J., & Zieger, B. (2026). Platelet Type Von Willebrand Disease – Diagnostic and Therapeutic Challenges. Hämostaseologie, 46(05), 348-357. https://doi.org/10.1055/a-2940-6179
Vancouver
Wiedenhoefer R, Boeckelmann D, Glonnegger H, Oldenburg J, Zieger B. Platelet Type Von Willebrand Disease – Diagnostic and Therapeutic Challenges. Hämostaseologie. 2026;46(05):348-357. doi:10.1055/a-2940-6179
BibTeX
@article{Wiedenhoefer2026,
author = {Wiedenhoefer, Rebekka and Boeckelmann, Doris and Glonnegger, Hannah and Oldenburg, Johannes and Zieger, Barbara},
title = {Platelet Type Von Willebrand Disease – Diagnostic and Therapeutic Challenges},
journal = {Hämostaseologie},
year = {2026},
volume = {46},
number = {05},
pages = {348--357},
doi = {10.1055/a-2940-6179}
}
EUVIMED